Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290688 | 0.91 | PDE2A (0.57) | PDE2ARPS6KB1BTKCHRM2CCR5 | |
| SCHEMBL18290683 | 0.87 | PDE2A (0.45) | PDE2ARPS6KB1BTK | |
| SCHEMBL20150757 | 0.85 | PDE2A (0.55) | PDE2ABTK | |
| SCHEMBL18285734 | 0.84 | PDE2A (0.60) | PDE2ACCR5 | |
| SCHEMBL20150749 | 0.83 | PDE2A (0.52) | PDE2APTGDR2 | |
| SCHEMBL20202571 | 0.82 | PDE2A (0.46) | PDE2ARPS6KB1BTK | |
| SCHEMBL20150748 | 0.81 | PDE2A (0.49) | PDE2APTGDR2BTK | |
| SCHEMBL20150758 | 0.81 | PDE2A (0.42) | PDE2ASCN9ASCN5APTGDR2 | |
| SCHEMBL20150744 | 0.81 | PDE2A (0.48) | PDE2APTGDR2 | |
| SCHEMBL18290691 | 0.77 | PDE2A (0.61) | PDE2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | PDE2A 2/4885SCN9A 2132/4885SCN5A 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.